 |
| |
| Jul-12-18 | Upgrade |
Goldman |
Sell → Neutral |
|
|
| Jun-27-18 | Initiated |
Bernstein |
Mkt Perform |
$129 |
|
| Apr-23-18 | Reiterated |
Citigroup |
Neutral |
$146 → $134 |
|
| Apr-18-18 | Reiterated |
Stifel |
Hold |
$145 → $135 |
|
| Jan-24-18 | Reiterated |
Stifel |
Hold |
$142 → $145 |
|
| Jan-12-18 | Reiterated |
Wells Fargo |
Outperform |
$155 → $160 |
|
| Jan-02-18 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Oct-18-17 | Reiterated |
Stifel |
Hold |
$140 → $142 |
|
| Oct-18-17 | Reiterated |
RBC Capital Mkts |
Outperform |
$144 → $147 |
|
| Oct-18-17 | Reiterated |
Leerink Partners |
Outperform |
$150 → $165 |
|
| Oct-16-17 | Reiterated |
Jefferies |
Buy |
$157 → $160 |
|
| Oct-11-17 | Upgrade |
Jefferies |
Hold → Buy |
|
|
| Oct-09-17 | Upgrade |
Wells Fargo |
Market Perform → Outperform |
|
|
| Sep-25-17 | Initiated |
Citigroup |
Neutral |
$140 |
|
| Sep-20-17 | Downgrade |
Goldman |
Neutral → Sell |
$125 → $130 |
|
| Jul-21-17 | Downgrade |
BTIG Research |
Neutral → Sell |
$110 |
|
| Jul-21-17 | Downgrade |
Alembic Global Advisors |
Neutral → Underweight |
|
|
| Jul-20-17 | Resumed |
Credit Suisse |
Outperform |
$148 |
|
| Jul-05-17 | Reiterated |
Morgan Stanley |
Overweight |
$135 → $140 |
|
| May-18-17 | Reiterated |
Stifel |
Hold |
$124 → $128 |
|
|
|
| Oct-16-18 08:52PM | The Rally We've Been Waiting For: Cramer's 'Mad Money' Recap (Tuesday 10/16/18) TheStreet.com |
| 07:54PM | [$$] Prescription Drugs Power Johnson & Johnson Results The Wall Street Journal |
| 07:54PM | [$$] Encouraging Test Results for Health-Care Giants The Wall Street Journal |
| 07:47PM | Edited Transcript of JNJ earnings conference call or presentation 16-Oct-18 12:30pm GMT Thomson Reuters StreetEvents |
| 07:20PM | Stocks can keep rallying as long as Fed doesn't keep push... CNBC Videos |
| 07:01PM | Jim Cramer: An Absence of Negatives Is a Real Positive TheStreet.com |
| 06:37PM | Cramer: As long as the Fed doesn't keep pushing rate hike... CNBC Videos |
| 06:11PM | Cramer: As long as the Fed doesn't keep pushing rate hikes, stocks can keep rallying CNBC |
| 05:23PM | Stocks surge, recovering some recent losses; Dow climbs 547 Associated Press |
| 05:00PM | 3 Stocks for Warren Buffett Fans Motley Fool |
| 04:56PM | What Happened in the Stock Market Today Motley Fool |
| 04:52PM | Stocks Soar on Earnings Octane Investopedia |
| 04:46PM | Stocks surge, recovering some recent losses; Dow climbs 547 Associated Press |
| 04:30PM | UnitedHealth, Johnson & Johnson and Morgan Stanley jump Associated Press |
| 04:11PM | Market focuses on revenue growth as the key to combating rising costs, interest rates CNBC |
| 04:05PM | Dow Surges More Than 540 Points on Strong Bank Earnings; Nasdaq Gains 2.9% TheStreet.com |
| 03:12PM | Johnson & Johnson (JNJ) Q3 2018 Earnings Conference Call Transcript Motley Fool |
| 03:01PM | Stock Market Storms Higher, But Can The Rally Be Trusted? Investor's Business Daily |
| 01:43PM | Will Tuesday's Earnings Reports Inspire a Stock Market Rebound? Zacks |
| 01:29PM | Johnson & Johnson Rises on Strong 3rd-Quarter Results GuruFocus.com |
| 01:20PM | Wall Street Rises on Strong Earnings GuruFocus.com |
| 01:17PM | A popular health-care fund is on pace for its best day since President Trump's election MarketWatch |
| 12:13PM | Market gets back to basics with a rally that shows fundamentals still rule CNBC |
| 11:55AM | J&J beats profit estimates, lifts outlook on pharma unit strength Reuters |
| 11:46AM | [$$] Encouraging Test Results for Health-Care Giants The Wall Street Journal |
| 11:31AM | Netflix Is Tonight's Big Report: Here's How I Would Play It TheStreet.com |
| 11:05AM | [$$] Prescription Drugs Power Johnson & Johnson Results The Wall Street Journal |
| 11:05AM | Johnson & Johnson Looks Healthier Than Ever Motley Fool |
| 10:54AM | Prescription drugs, lower taxes, power J&J 3Q beat Associated Press |
| 10:39AM | Q3 Earnings Reports: MSFT, NFLX, GS, MS, UNH, JNJ Zacks |
| 10:28AM | Johnson & Johnson Bumps Full-Year Earnings Guidance Higher After Solid Q3 TheStreet.com |
| 10:26AM | Q3 Earnings Results Impress: GS, MS, UNH & More Zacks |
| 10:08AM | Johnson & Johnson edges past profit estimates, lifts outlook Reuters |
| 10:07AM | UPDATE 2-Johnson & Johnson edges past profit estimates, lifts outlook Reuters |
| 10:04AM | J&J applauds U.S. proposal on drug prices in TV ads Reuters |
| 09:52AM | J&J (JNJ) Beats Earnings & Sales Estimates in Q3, Ups View Zacks |
| 09:26AM | Dow's earnings reporters providing a 92-point boost to futures' rally MarketWatch |
| 09:08AM | [$$] Stocks to Watch: Goldman, Morgan, Walmart, U.S. Steel The Wall Street Journal |
| 08:53AM | U.S. Stocks Set For Solid Open as Q3 Earnings Impress; Goldman Boosts Dow TheStreet.com |
| 07:55AM | Johnson & Johnson (JNJ) Surpasses Q3 Earnings and Revenue Estimates Zacks |
| 07:54AM | Stocks making the biggest move premarket: MS, GS, UNH, JNJ, WMT & more CNBC |
| 07:47AM | Netflix, Goldman Sachs, Paul Allen, Google and Ford - 5 Things You Must Know TheStreet.com |
| 07:30AM | US STOCKS-Futures rise on upbeat results from UnitedHealth, Morgan Stanley Reuters |
| 07:02AM | Johnson & Johnson reports Q3 profit, revenue beats MarketWatch |
| 06:47AM | Johnson & Johnson quarterly profit rises 4.5 percent Reuters |
| 06:40AM | Johnson & Johnson Reports 2018 Third-Quarter Results: PR Newswire |
| 06:30AM | Johnson & Johnson to Host Earnings Call ACCESSWIRE |
| 06:14AM | Johnson & Johnson tops third-quarter earnings, revenue estimates CNBC |
| Oct-15-18 05:12PM | Johnson & Johnson CEO Discusses Drug Pricing Meredith Videos |
| 03:53PM | 5 Top Stock Trades for Tuesday: Trading Bank Earnings InvestorPlace |
| 03:00PM | 7 Stocks to Buy and Hold Through Any Market Selloff InvestorPlace |
| 02:32PM | Johnson & Johnson Q3 Earnings Preview Benzinga |
| 11:16AM | Drugmakers will soon talk about price in ads but not as explicitly as Trump administration wants CNBC |
| 08:35AM | JPMorgan, Wells Fargo, Citigroup, Johnson & Johnson, Netflix and Schlumberger are part of Zacks Earnings Preview Zacks |
| Oct-12-18 06:11PM | Cramer's game plan: Increased volatility could turn positive with help from Trump, Fed CNBC |
| 05:53PM | Banks Provide Positive Start to Q3 Earnings Season Zacks |
| 02:31PM | This 1 Stock Could Send the Entire Healthcare Sector Soaring -- or Plunging Motley Fool |
| 10:25AM | Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal Zacks |
| 10:04AM | J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion Zacks |
| 09:35AM | Is a Surprise Coming for Johnson & Johnson (JNJ) This Earnings Season? Zacks |
| 09:01AM | Dow 30 Stock Roundup: Walgreens' Earnings Top, UTX Board OKs Dividend Hike Zacks |
| 08:20AM | 3 Big Pharma Stocks Racing Along the Road to China Motley Fool |
| 08:12AM | Jury clears J&J of liability in New Jersey talc cancer case Reuters |
| Oct-11-18 03:58PM | Here's Why Arrowhead Pharmaceuticals Skyrocketed Almost 30% in September Motley Fool |
| 03:25PM | Jury clears J&J of liability in New Jersey talc cancer case Reuters |
| 10:21AM | J&J (JNJ) to Set the Ball Rolling for Pharma Q3 Earnings Zacks |
| Oct-10-18 05:45PM | Johnson & Johnson (JNJ) Stock Moves -1.06%: What You Should Know Zacks |
| 11:38AM | 5 Healthcare Stocks to Buy for Complete Portfolio Wellness InvestorPlace |
| 10:35AM | J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study Zacks |
| 10:23AM | Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates Zacks |
| Oct-09-18 04:11PM | 4 Reasons to Be Wary of This Animal Health IPO Motley Fool |
| 03:12PM | 10 S&P 500 Stocks to Buy for the Long Term InvestorPlace |
| 12:00PM | Orchestra BioMed Adds Three Industry Leaders to Strategic Advisory Board GlobeNewswire |
| 10:45AM | ARWR Stock Sinks After Signing a Big Collaboration Deal InvestorPlace |
| 10:30AM | Johnson & Johnson (JNJ) Q3 Earnings Preview: Here's What to Look Out For Zacks |
| 10:05AM | Here's Why Geron Plummeted 69% in September Motley Fool |
| 09:46AM | J&J's Stelara succeeds in chronic bowel disease study Reuters |
| Oct-08-18 06:05PM | Johnson & Johnson Offers an Attractive Investment Proposition GuruFocus.com |
| 12:00PM | Johnson & Johnson Vision Launches Worldwide Campaign to #SpotlightSight in Honor of World Sight Day PR Newswire |
| 11:15AM | Are These Beaten-Down Clinical-Stage Biotech Stocks Buys? Motley Fool |
| 09:25AM | Geron Stock: Buy, Sell, or Hold? Motley Fool |
| 08:01AM | Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip? Motley Fool |
| Oct-05-18 01:12PM | 8 Stocks to Buy That Will Never Go Out of Style InvestorPlace |
| 11:30AM | J&J Inks Deal With Arrowhead for Promising Liver Candidate Zacks |
| 10:22AM | MARKETS: Nike, McDonald's leading the Dow higher, as big banks get a bump Yahoo Finance Video |
| 09:57AM | Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data Zacks |
| Oct-04-18 06:28PM | MARKETS: Don't freak out about today's selloff, but retail is still in trouble Yahoo Finance Video |
| 02:49PM | J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion Reuters |
| 02:24PM | 7 Healthcare Stocks to Buy Right Now InvestorPlace |
| 11:30AM | Stocks - Apple, Amazon Fall in Pre-market; Barnes & Noble Surges Investing.com |
| 10:57AM | Health-Care Stocks High Valuations May Not Be a Problem Barrons.com |
| 10:12AM | Arrowhead Announces $3.7B License Agreement With Janssen For Gene-Silencing Drug Benzinga |
| 09:37AM | J&J's Phase III Data Shows Switch to its HIV Drug Beneficial Zacks |
| 09:19AM | J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion Reuters |
| 07:59AM | The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut Benzinga |
| 07:52AM | UPDATE: Arrowhead Pharma stock surges 19% on news of $3.7 billion license agreement with Janssen MarketWatch |
| 03:20AM | Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US Moody's |
| Oct-03-18 05:13PM | Platinum Equity completes $2B purchase of J&Js LifeScan American City Business Journals |
| 11:14AM | Here's Why J&J (JNJ) is a Good Bet in a Troubled Market Zacks |
| 10:23AM | Novartis, Boston Pharma Ink Deal for 3 Anti-Infective Drugs Zacks |
|
|
|
|
| Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The company's Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension diseases. Its Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Kapusta Ronald A | Controller, CAO | Sep 07 | Sale | 137.18 | 7,899 | 1,083,607 | 25,725 | Sep 11 03:53 PM | | Sneed Michael E | EVP, Global Corp Aff & COO | Aug 27 | Option Exercise | 58.33 | 29,000 | 1,691,570 | 59,124 | Aug 28 04:03 PM | | Sneed Michael E | EVP, Global Corp Aff & COO | Aug 27 | Sale | 134.80 | 29,000 | 3,909,084 | 30,124 | Aug 28 04:03 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 15 | Option Exercise | 90.44 | 155,342 | 14,049,130 | 357,906 | Feb 20 07:46 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 15 | Sale | 129.86 | 155,342 | 20,172,401 | 202,564 | Feb 20 07:46 PM | | Caruso Dominic J | Exec VP, Finance; CFO | Feb 09 | Option Exercise | 0.00 | 10,601 | 0 | 154,703 | Feb 13 06:54 PM | | Duato Joaquin | Exec VP, WW Chair, Pharma | Feb 09 | Option Exercise | 0.00 | 9,812 | 0 | 78,348 | Feb 13 06:54 PM | | Fasolo Peter | Exec VP, Chief HR Officer | Feb 09 | Option Exercise | 0.00 | 5,830 | 0 | 69,992 | Feb 13 06:54 PM | | Gorsky Alex | Chairman, CEO | Feb 09 | Option Exercise | 0.00 | 33,165 | 0 | 285,990 | Feb 13 06:54 PM | | PETERSON SANDRA E | Exec VP, Group WW Chairman | Feb 09 | Option Exercise | 0.00 | 11,445 | 0 | 70,205 | Feb 13 06:54 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 09 | Option Exercise | 0.00 | 13,252 | 0 | 181,655 | Feb 13 06:55 PM | | Ullmann Michael H | Exec VP, General Counsel | Feb 09 | Option Exercise | 0.00 | 5,953 | 0 | 115,257 | Feb 13 06:55 PM | | Kapusta Ronald A | Controller, CAO | Feb 09 | Option Exercise | 0.00 | 2,702 | 0 | 32,666 | Feb 13 06:55 PM | | Mesquita Jorge S. | Exec VP, WW Chair, Consumer | Feb 02 | Option Exercise | 0.00 | 32,688 | 0 | 32,688 | Feb 06 04:21 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Oct 31 | Option Exercise | 0.00 | 75,492 | 0 | 203,142 | Nov 02 05:01 PM |
|
|
|
|
|
|
